INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Rocket Lab USA, Inc. (RKLB) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm 

ATLANTA, Feb. 28, 2025 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against Rocket Lab USA, Inc (“Rocket Lab” or the “Company”) (NASDAQ: RKLB). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about QCI’s business, operations, and prospects, including allegations that: (1) the Company’s plans for three barge landing tests were significantly delayed; (2) a critical potable water problem was not scheduled to be fixed until January 2026, which delayed preparation of the launch pad; (3) as a result of the foregoing, there was a substantial risk that Rocket Lab’s Neutron rocket would not launch in mid-2025; (4) Neutron’s only contract was made at a discount with an unreliable partner; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you bought shares of Quantum Computing between November 12, 2024 and February 25, 2025, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/rocket-lab/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is April 28, 2025.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]



Calix Launches ASM1001 High-Availability Service Aggregation System So Broadband Providers Can Build Resilient Networks That Scale

Calix Launches ASM1001 High-Availability Service Aggregation System So Broadband Providers Can Build Resilient Networks That Scale

The launch of the Intelligent Access ASM1001 system for the Calix Broadband Platform allows customers to maximize BEAD funding opportunities by delivering performance-optimized Layer 3 service aggregation deeper into the network, enabling high-availability broadband services for any market

LONDON & SAN JOSE, Calif.–(BUSINESS WIRE)–Calix, Inc. (NYSE: CALX) expands its comprehensive Aggregation Service Manager (ASM) portfolio for the Calix Broadband Platform with the Intelligent Access™ ASM1001 system while adding new operational efficiency capabilities for Calix Cloud®. The ASM1001 drives advanced Layer 3 routing deeper into the network, enabling broadband service providers (BSPs) to build a resilient, distributed service aggregation architecture that optimizes performance and streamlines operations. Updates to Calix Operations Cloud (part of Calix Cloud) give BSPs extensive monitoring, insights, and troubleshooting on service aggregation system health and VPN service connectivity.

Designed for the access network edge, the ASM1001 joins the centralized, high-capacity ASM5001 and ASM3001 subscriber management systems in helping BSPs simplify network operations and improve efficiency across any network, location, or technology. With unprecedented state and federal funding available to expand broadband access—especially in rural and underserved areas—BSPs can leverage the ASM1001 and new cloud capabilities for the Calix Platform to help scale and grow their businesses. The Calix ASM portfolio and additional Intelligent Access systems create an end-to-end solution for broadband service delivery that is fully eligible for Broadband Equity, Access, and Deployment (BEAD) program funding.

Leveraging Calix Platform updates and the new ASM1001, BSPs have:

  • More flexible options to build efficient, resilient networks in remote locations. Expanding the Calix ASM portfolio, the ASM1001 gives BSPs flexibility to deploy service aggregation and routing functions deeper into the network for better performance, streamlined operations, and improved network uptime. The ASM1001 for Intelligent Access is powered by AXOS® and offers temperature-hardened, Layer 3, 100G aggregation in a compact form factor. This optimizes performance, simplifies provisioning and management, and eliminates the need to add remote cabinets or utility buildings—lowering project costs and accelerating time to market.
  • End-to-end visibility with Operations Cloud for faster troubleshooting. New enhancements in Operations Cloud improve visibility for the Calix ASM portfolio, ideal for growing networks. With centralized VPN status monitoring, operators can easily identify impacts to the network without troubleshooting individual systems. Additionally, enhanced health monitoring and reporting capabilities seamlessly monitor network utilization and proactively identify and notify BSPs of XGS-PON and GPON service-impacting issues. Both innovations result in fewer trouble calls, faster issue resolution, and a more reliable experience for subscribers in dispersed, rural communities, complementing the innovation of the ASM1001.
  • Hands-on success and guidance to future-proof their network. Leveraging best practices from Calix Success™, BSPs can tap into deep technical expertise for the Intelligent Access solution. Success Guidance can assist Calix customers with planning and executing best practices to achieve their growth and performance goals, accelerate time to market, and modernize their network architecture.

“We selected the ASM1001 because it allows us to serve customers in remote locations more efficiently and at a reduced total cost,” said Michael Prather, chief technology officer at Totelcom Communications. “It’s flexible, compact, cost effective, and meets our access aggregation and routing needs. Since it is part of the Calix Platform, our team can save time using the AXOS software, hardware, and Calix Cloud they are already familiar with. We’re excited to simplify our operations further and capitalize on growth opportunities with the Intelligent Access solution.”

“The ASM1001 gives broadband service providers greater flexibility to move service aggregation deeper into the network,” said Shane Eleniak, chief product officer at Calix. “With an expansive Intelligent Access system portfolio for the Calix Platform, BSPs can seamlessly deploy exceptional, highly available broadband experiences across a wide range of environments—from centralized locations in densely populated areas to highly distributed, rural communities. With historic state and federal funding becoming available to support broadband initiatives, Calix customers are well-positioned to grow their businesses with a comprehensive, BEAD-compliant solution and deliver even more value to their subscribers.”

Reach more subscribers, regardless of location, with Intelligent Access on the Calix Broadband Platform.

About Calix

Calix, Inc. (NYSE: CALX)—Calix is a platform, cloud, and managed services company. Broadband service providers leverage Calix’s broadband platform, cloud, and managed services to simplify their operations, subscriber engagement, and services; innovate for their consumer, business, and municipal subscribers; and grow their value for members, investors, and the communities they serve.

Our end-to-end platform and managed services democratize the use of data—enabling our customers of any size to operate efficiently, acquire subscribers, and deliver exceptional experiences. Calix is dedicated to driving continuous improvement in partnership with our growing ecosystem to support the transformation of our customers and their communities.

This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix’s business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix’s results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at www.sec.gov.

Calix and the Calix logo are trademarks or registered trademarks of Calix and/or its affiliates in the U.S. and other countries. A listing of Calix’s trademarks can be found at https://www.calix.com/legal/trademarks.html. Third-party trademarks mentioned are the property of their respective owners.

Press Inquiries:

Zach Burger

669-369-1991

[email protected]

Investor Inquiries:

Nancy Fazioli

[email protected]

KEYWORDS: Europe United States United Kingdom North America California

INDUSTRY KEYWORDS: Data Management Communications Technology Telecommunications Software Networks Public Relations/Investor Relations

MEDIA:

Logo
Logo

Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company’s Initial Public Offering (“IPO”) on September 15, 2023.

On February 7, 2025, a complaint was filed against the Company, certain of its current officers and directors, and underwriters, alleging that in connection with its IPO, Defendants made false and/or misleading statements and/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder (“MDD”) to show that Navacaprant offered a statistically significant improvement in treating MDD; (ii) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (iii) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

When investors learned the truth, Neumora’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Neumora’s securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before April 7, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) for violations of the federal securities laws on behalf of investors who purchased or acquired TransMedics common stock between February 28, 2023 and January 10, 2025, inclusive (the “Class Period”).

On February 14, 2025, a complaint was filed against the Company and certain of its officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (ii) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (iii) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk.

When investors learned the truth, TransMedics’ common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in TransMedics’ securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before April 15, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies Venture Global, Inc. (“Venture Global” or the “Company”) (NYSE: VG) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Venture Global, Inc. (“Venture Global” or the “Company”) (NYSE: VG) for violations of the federal securities laws on behalf of investors who purchased or acquired Venture Global common stock at the time of the Company’s Initial Public Offering (“IPO”) on January 24, 2025.

On February 17, 2025, a complaint was filed against the Company, certain of its current officers and directors, alleging that in connection with its IPO, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Venture Global’s ability to deliver liquefied natural gas (LNG) to the world and to continue development of its five natural gas liquefication and export projects depended on customer contracts; (2) Venture Global was facing legal challenges from existing large clients, such as BP and Shell, due to delays in supply contracts as it commissioned its projects; and (3) accordingly, Venture Global’s business and/or financial prospects were overstated.

When investors learned the truth, Venture Global’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $50,000 in Venture Global’s securities, and wish to participate, or learn more, please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before April 18, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected] 

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies Integral Ad Science Holding Corp. (“IAS” or the “Company”) (NASDAQ: IAS) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $300,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Integral Ad Science Holding Corp. (“IAS” or the “Company”) (NASDAQ: IAS) for violations of the federal securities laws on behalf of investors who purchased or acquired IAS common stock between March 2, 2023, and February 27, 2024, inclusive (the “Class Period”).

On January 29, 2025, a complaint was filed against the Company and certain of its current and former officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) that IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (iii) that pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) that the risks that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.

When investors learned the truth, IAS’ common stock declined precipitously, injuring investors.

If you suffered a loss of more than $300,000 in IAS’ securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before March 31, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies Crocs, Inc. (“Crocs” or the “Company”) (NASDAQ: CROX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Crocs, Inc. (“Crocs” or the “Company”) (NASDAQ: CROX) for violations of the federal securities laws on behalf of investors who purchased or acquired Crocs common stock between November 3, 2022, and October 28, 2024, inclusive (the “Class Period”).

On January 22, 2025, a complaint was filed against the Company and certain of its officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the nature and sustainability of HEYDUDE’s revenue growth by concealing that 2022 revenue growth was driven, in large part, by Crocs’ efforts to stock third-party wholesalers and retailers following the February 2022 acquisition of HEYDUDE; and (ii) that as Crocs’ retail partners began to destock this excess inventory, waning product demand further negatively impacted Crocs’ financial results.

When investors learned the truth, Croc’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Croc’s securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before March 24, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected] 

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).

On January 13, 2024, a complaint was filed against the Company and certain of its current and former officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue; (ii) Pacira knew that the ‘495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.’s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel; and (iii) therefore, when the ‘495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira’s revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent.

When investors learned the truth, Pacira’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Pacira’s securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before March 14, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQ: FTAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQ: FTAI) for violations of the federal securities laws on behalf of investors who purchased or acquired FTAI common stock between July 23, 2024 and January 15, 2025, inclusive (the “Class Period”).

On January 17, 2025, a complaint was filed against the Company and certain of its officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company reported one-time engine sales as Maintenance Repair & Overhaul revenue when FTAI only performs limited repair and maintenance work on the engine assets sold; (2) FTAI presents whole engine sales as individual module sales, thereby overstating sales and demand; (3) the Company depreciates engines that are not on lease, which misleadingly lowers the reported cost of goods sold and inflates EBITDA; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

When investors learned the truth, FTAI’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in FTAI’s securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before March 18, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.



Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) for violations of the federal securities laws on behalf of investors who purchased or acquired Novo common stock between November 2, 2022 to December 19, 2024, inclusive (the “Class Period”).

On January 24, 2025, a complaint was filed against the Company and certain of its officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Novo’s projected successful outcome of Novo’s phase 3 CagriSema study on obesity, named “REDEFINE-1,” while avoiding discussions centered around dosage tolerability; (ii) Novo’s repeated optimistic claims that CagriSema would achieve at least 25% weight loss in the REDEFINE-1 study fell short of reality; and (iii) the utilization of the “flexible protocol” limited the study’s ability to effectively provide weight loss data on the dosage tested, suggesting either that tolerability was significantly worse than anticipated, resulting in patients titrating down their dosages to avoid complications, or that the patient selection process was rushed, leading to the onboarding of patients that did not desire to even achieve the 25% weight loss Novo sought to demonstrate.

When investors learned the truth, Novo’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $200,000 in Novo’s securities, and wish to participate, or learn more, click here, or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Vincent R. Cappucci Jr. ([email protected]).

Any investor who wishes to serve as Lead Plaintiff must act before March 25, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected] 

SOURCE: Lowey Dannenberg P.C.